Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Keros Therapeutics, Inc.
Trials need funding. See this company's dilution risk and cash position.
- Phase 2Withdrawn
A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).
KER-047
Iron Deficiency Anemia
NCT05927012Enrollment0StartNov 2023est.Primary CompletionAug 2025est.CompletionJan 2026est. - Phase 2Terminated
A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).
Dose A KER-012, Dose B KER-012
Pulmonary Arterial Hypertension
NCT05975905Enrollment113StartOct 2023Primary CompletionMar 2025CompletionMar 2025 - Phase 2Recruiting
Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy
KER-065
Duchenne Muscular Dystrophy
NCT07704099Enrollment36StartSep 2026Primary CompletionAug 2028est.CompletionSep 2028est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 2 | Withdrawn | KER-047 | NCT05927012 |
| Phase 2 | Terminated | Dose A KER-012, Dose B KER-012 | NCT05975905 |
| Phase 2 | Recruiting | KER-065 | NCT07704099 |